Dr. Reddy's Laboratories Ltd. (DRREDDY) - Stock Overview & Analysis

Search your stocks

Profile

DRREDDYDr. Reddy's Laboratories Ltd.

₹1319.5-0.24%

Market Cap

₹1,06,835.27 Cr

Stock P/E

15.50

ROCE

26.86%

ROE

21.76%

Book Value

₹1686.06

You might have missed

No Recent News

No recent news available for this stock.

Shareholding

Holdings

Distribution

Promoter

Institution

Public

Others

Financials

YoY Net Sales

EPS Growth

Operating Margin

From Last Concall

POSITIVES

•
11% YoY revenue growth in Q1FY26, signaling durable momentum.
•
EBITDA margin at 27%, indicating margin resilience despite US softness.

NEGATIVES

•
US North America Generics softness with 17% YoY decline, driven by price erosion.
•
US FDA inspections at FTO-11 CTA sites, seven observations, regulatory risk.

Peers Summary

Sector Leader

Dr. Reddy's Laboratories Ltd. stands out in the pharmaceuticals sector with strong growth metrics, impressive profitability, and attractive valuation ratios. Compared to its peers, it shows significant advantages in revenue growth and return metrics, positioning it as a leader in the industry.

Key Points

• Dr. Reddy's Laboratories has the highest 3-Year Revenue Growth at 13.72%.
• It exhibits robust profitability with a leading ROCE of 26.86%.
• Valuation metrics suggest Dr. Reddy's is undervalued with a PEG ratio of 0.19.

Top Performers

Dr. Reddy's Laboratories Ltd.

Highest 3-Year Revenue Growth (13.72%) and strong profitability metrics.

Mankind Pharma Ltd.

Strong growth trajectory with a 3-Year Revenue Growth of 155.25%.

Cipla Ltd.

Solid ROE of 16.63% and low debt equity ratio.